Literature DB >> 34128195

Dapagliflozin Improves the Clinical Outcomes of Patients with Chronic Kidney Disease and Albuminuria.

Stephanie A Patrick1, Tracey D Dabal1, Christopher D Jackson2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34128195      PMCID： PMC8390623          DOI： 10.1007/s11606-021-06871-w

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   6.473


× No keyword cloud information.
  4 in total

1.  Dapagliflozin in Patients with Chronic Kidney Disease.

Authors:  Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal:  N Engl J Med       Date:  2020-09-24       Impact factor: 91.245

2.  Diabetes and CKD in the United States Population, 2009-2014.

Authors:  Leila R Zelnick; Noel S Weiss; Bryan R Kestenbaum; Cassianne Robinson-Cohen; Patrick J Heagerty; Katherine Tuttle; Yoshio N Hall; Irl B Hirsch; Ian H de Boer
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-20       Impact factor: 8.237

3.  Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.

Authors:  Paola Fioretto; Stefano Del Prato; John B Buse; Ronald Goldenberg; Francesco Giorgino; Daniel Reyner; Anna Maria Langkilde; C David Sjöström; Peter Sartipy
Journal:  Diabetes Obes Metab       Date:  2018-07-10       Impact factor: 6.577

4.  Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.

Authors:  Claire C J Dekkers; David C Wheeler; C David Sjöström; Bergur V Stefansson; Valerie Cain; Hiddo J L Heerspink
Journal:  Nephrol Dial Transplant       Date:  2018-11-01       Impact factor: 5.992
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.